Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects

NCT02287779 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02287779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 19, 2015
Completion date
June 19, 2015
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis